Total Funding
83
60
Total FundingPost-IPO Equity raised
Growth Score 83 in past quarter
-7 pts
Heat Score 60 in past quarter
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
110598
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
- Frederick Graff: Chief Commercial Officer
- Ryan Lake: Chief Financial Officer
About the Company
Recro Pharma is a clinical-stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. The company's lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo-controlled trial demonstrating pain relief.
It was founded
in 2007 and headquartered in Malvern, Pennsylvania.
Women Founded

